Species: | Rabbit |
Applications: | WB IP IF FC |
Immunogen Range: | A synthetic phosphopeptide corresponding to residues surrounding Thr286 of cyclin D1 |
Clonality: | Monoclonal Antibody |
Isotype: | IgG |
GENE ID: | 595 |
Swiss Prot: | P24385 |
Synonyms: | BCL1, D11S287E, PRAD1, U21B31 |
Purification: | Affinity purification |
Storage: | Store at -20°C in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Avoid freeze/thaw cycles. |
Background: | Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins (1). The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to affect progression through the restriction point and Rb-dependent entry into S-phase (2). The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression (3). Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of protein expression and phosphorylation-dependent degradation (4).Aberrant expression of cyclin D1 is associated with many forms of cancer, including B cell lymphomas. Gene translocation or amplification of the cyclin D1 gene can directly contribute to oncogenesis (2). Cyclin D1 also plays a critical role in mammary tissue maturation (5). Phosphorylation of cyclin D1 at Thr286 by glycogen synthase kinase 3β (4) or through the Ras/Raf/MEK/MAPK pathway (6) enhances its ubiquitination and proteasomal degradation. |
Caculated MW: | 36 kDa |
Observed MW: | Refer to Figures |
Applications: |
WB 1:1000 IF 1:2000 FC 1:1600 |
Reacitivity: | Human, Monkey |